Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 165

1.

Advantages and disadvantages of discrete-event simulation for health economic analyses.

Caro JJ, Möller J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Mar 25:1-3. [Epub ahead of print] No abstract available.

PMID:
26967022
2.

Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.

Caro JJ.

Pharmacoeconomics. 2016 Mar 9. [Epub ahead of print]

PMID:
26961779
3.

Implementation of Population Dynamics In Modelling Health And Budget Impact of An Intervention for A Chronic Disease With Multiple Disease Subtypes.

Tran-Duy A, Boonen A, Caro JJ, Severens JL.

Value Health. 2015 Nov;18(7):A700. doi: 10.1016/j.jval.2015.09.2618. Epub 2015 Oct 20. No abstract available.

PMID:
26533921
4.

What Is Insufficient about Validation?

Caro JJ.

Med Decis Making. 2015 Oct;35(7):817. doi: 10.1177/0272989X15598743. Epub 2015 Jul 30. No abstract available.

PMID:
26229082
5.

Psst, have I got a model for you . . .

Caro JJ.

Med Decis Making. 2015 Feb;35(2):139-41. doi: 10.1177/0272989X14559729. Epub 2014 Nov 20. No abstract available.

PMID:
25413367
6.

Decision-analytic models: current methodological challenges.

Caro JJ, Möller J.

Pharmacoeconomics. 2014 Oct;32(10):943-50. doi: 10.1007/s40273-014-0183-5.

PMID:
24986039
7.

Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.

Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A.

Health Econ. 2015 Apr;24(4):481-90. doi: 10.1002/hec.3041. Epub 2014 Mar 4.

8.

Use of relative effectiveness information in reimbursement and pricing decisions in Europe.

van Nooten F, Caro JJ.

J Comp Eff Res. 2013 Jan;2(1):33-44. doi: 10.2217/cer.12.71.

PMID:
24236519
9.

ISPOR-SMDM task force's recommendations for good modeling practices-reply to letter to the editor by Corro Ramos.

Caro JJ, Eddy DM, Hollingworth W, Tsevat J, McDonald KM, Wong JB, Briggs AH, Siebert U, Kuntz KM.

Value Health. 2013 Sep-Oct;16(6):1108. doi: 10.1016/j.jval.2013.06.016. No abstract available.

10.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
11.

How relevant is cost-effectiveness anyway?

Caro JJ.

Eur Heart J. 2013 Jan;34(4):245-6. No abstract available.

12.

Medical planning and response for a nuclear detonation: a practical guide.

Coleman CN, Adams S, Adrianopoli C, Ansari A, Bader JL, Buddemeier B, Caro JJ, Casagrande R, Case C Jr, Caspary K, Chang AS, Chang HF, Chao N, Cliffer KD, Confer D, Deitchman S, Derenzo EG, Dobbs A, Dodgen D, Donnelly EH, Gorman S, Grace MB, Hatchett R, Hick JL, Hrdina C, Jones R, Kane E, Knebel A, Koerner JF, Laffan AM, Larson L, Livinski A, Mackinney J, Maidment BW, Manning R, Marinissen MJ, Martin C, Michael G, Murrain-Hill P, Nemhauser JB, Norwood AE, Nystrom S, Raheem M, Redlener I, Sheehan K, Simon SL, Taylor TP, Toner E, Wallace KS, Wieder J, Weinstock DM, Wiley AL Jr, Yeskey K, Miller CW, Whitcomb RC Jr.

Biosecur Bioterror. 2012 Dec;10(4):346-71. doi: 10.1089/bsp.2012.1025. Erratum in: Biosecur Bioterror. 2013 Mar;11(11):88. Miller, Charles W [added]; Whitcomb, Robert C Jr [added].

PMID:
23244500
13.

User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents.

Coleman CN, Hrdina C, Casagrande R, Cliffer KD, Mansoura MK, Nystrom S, Hatchett R, Caro JJ, Knebel AR, Wallace KS, Adams SA.

Disaster Med Public Health Prep. 2012 Dec;6(4):408-14. doi: 10.1001/dmp.2012.46a.

PMID:
23241473
14.

How cost-effective are drugs and devices used in cardiology?

Caro JJ.

Eur Heart J. 2012 Oct;33(19):2372-3. No abstract available.

15.

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR−SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):843-50. doi: 10.1016/j.jval.2012.04.012.

16.

Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.

Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J; ISPOR-SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):821-7. doi: 10.1016/j.jval.2012.04.013.

17.

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.

Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):796-803. doi: 10.1016/j.jval.2012.06.012.

18.

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR-SMDM Modeling Good Research Practices Task Force.

Med Decis Making. 2012 Sep-Oct;32(5):733-43.

PMID:
22990088
19.

Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4.

Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J.

Med Decis Making. 2012 Sep-Oct;32(5):701-11.

PMID:
22990085
20.

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force.

Med Decis Making. 2012 Sep-Oct;32(5):667-77. Review.

PMID:
22990082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk